Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy

Mikaela Dell'Oro; Michala Short; Puthenparampil Wilson; Eva Bezak

doi:10.1016/j.critrevonc.2021.103415

Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy

Mikaela Dell'Oro, Michala Short, Puthenparampil Wilson, Eva Bezak

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Background: Proton radiotherapy (PT) is used increasingly for paediatric brain cancer patients. However, as demonstrated here, the knowledge on normal tissue dose constraints, to minimize side-effects, for this cohort is limited.

Methods: A search strategy was systematically conducted on MEDLINE® database. 65 papers were evaluated ranging from 2013 to 2021.

Results: Large variations in normal tissue tolerance and toxicity reporting across PT studies makes estimation of normal tissue dose constraints difficult, with the potential for significant late effects to go unmeasured. Mean dose delivered to the pituitary gland varies from 20 to 30 Gy across literature. Similarly, the hypothalamic dose delivery ranges from 20 to 54.6 Gy for paediatric patients.

Conclusion: There is a significant lack of radiobiological data for paediatric brain cancer patients undergoing proton therapy, often using data from x-ray radiotherapy and adult populations. The way forward is through standardisation of reporting in order to validate relevant dose constraints.

Original language	English
Article number	103415
Journal	Critical Reviews in Oncology/Hematology
Volume	164
DOIs	https://doi.org/10.1016/j.critrevonc.2021.103415
Publication status	Published - Aug 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2021.103415

Cite this

@article{7eaaf9018ed14e1dbf67a2d13284018b,

title = "Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy",

abstract = "Background: Proton radiotherapy (PT) is used increasingly for paediatric brain cancer patients. However, as demonstrated here, the knowledge on normal tissue dose constraints, to minimize side-effects, for this cohort is limited.Methods: A search strategy was systematically conducted on MEDLINE{\textregistered} database. 65 papers were evaluated ranging from 2013 to 2021.Results: Large variations in normal tissue tolerance and toxicity reporting across PT studies makes estimation of normal tissue dose constraints difficult, with the potential for significant late effects to go unmeasured. Mean dose delivered to the pituitary gland varies from 20 to 30 Gy across literature. Similarly, the hypothalamic dose delivery ranges from 20 to 54.6 Gy for paediatric patients.Conclusion: There is a significant lack of radiobiological data for paediatric brain cancer patients undergoing proton therapy, often using data from x-ray radiotherapy and adult populations. The way forward is through standardisation of reporting in order to validate relevant dose constraints.",

keywords = "Brain tumour, long-term side effects, Normal tissue tolerance, proton therapy, paediatric",

author = "Mikaela Dell'Oro and Michala Short and Puthenparampil Wilson and Eva Bezak",

year = "2021",

month = aug,

doi = "10.1016/j.critrevonc.2021.103415",

language = "English",

volume = "164",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier",

}

TY - JOUR

T1 - Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy

AU - Dell'Oro, Mikaela

AU - Short, Michala

AU - Wilson, Puthenparampil

AU - Bezak, Eva

PY - 2021/8

Y1 - 2021/8

N2 - Background: Proton radiotherapy (PT) is used increasingly for paediatric brain cancer patients. However, as demonstrated here, the knowledge on normal tissue dose constraints, to minimize side-effects, for this cohort is limited.Methods: A search strategy was systematically conducted on MEDLINE® database. 65 papers were evaluated ranging from 2013 to 2021.Results: Large variations in normal tissue tolerance and toxicity reporting across PT studies makes estimation of normal tissue dose constraints difficult, with the potential for significant late effects to go unmeasured. Mean dose delivered to the pituitary gland varies from 20 to 30 Gy across literature. Similarly, the hypothalamic dose delivery ranges from 20 to 54.6 Gy for paediatric patients.Conclusion: There is a significant lack of radiobiological data for paediatric brain cancer patients undergoing proton therapy, often using data from x-ray radiotherapy and adult populations. The way forward is through standardisation of reporting in order to validate relevant dose constraints.

AB - Background: Proton radiotherapy (PT) is used increasingly for paediatric brain cancer patients. However, as demonstrated here, the knowledge on normal tissue dose constraints, to minimize side-effects, for this cohort is limited.Methods: A search strategy was systematically conducted on MEDLINE® database. 65 papers were evaluated ranging from 2013 to 2021.Results: Large variations in normal tissue tolerance and toxicity reporting across PT studies makes estimation of normal tissue dose constraints difficult, with the potential for significant late effects to go unmeasured. Mean dose delivered to the pituitary gland varies from 20 to 30 Gy across literature. Similarly, the hypothalamic dose delivery ranges from 20 to 54.6 Gy for paediatric patients.Conclusion: There is a significant lack of radiobiological data for paediatric brain cancer patients undergoing proton therapy, often using data from x-ray radiotherapy and adult populations. The way forward is through standardisation of reporting in order to validate relevant dose constraints.

KW - Brain tumour

KW - long-term side effects

KW - Normal tissue tolerance

KW - proton therapy

KW - paediatric

U2 - 10.1016/j.critrevonc.2021.103415

DO - 10.1016/j.critrevonc.2021.103415

M3 - Review article

C2 - 34242771

SN - 1040-8428

VL - 164

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103415

ER -

Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this